Lampalizumab
Lampalizumab is an experimental drug that was developed by Genentech, a biotechnology company based in the United States. The drug was designed to treat geographic atrophy, a form of age-related macular degeneration (AMD) that can lead to severe vision loss and blindness.
History[edit | edit source]
Lampalizumab was first developed by Genentech, a member of the Roche Group. The drug was designed to target and inhibit the activity of complement factor D, a protein that plays a key role in the development of geographic atrophy.
In 2013, Genentech announced the results of a Phase II clinical trial, which suggested that lampalizumab could slow the progression of geographic atrophy. However, two Phase III clinical trials (known as the Spectri and Chroma trials) failed to confirm these results.
Mechanism of Action[edit | edit source]
Lampalizumab is a monoclonal antibody that targets complement factor D. By inhibiting this protein, the drug is thought to reduce the inflammatory response that contributes to the development of geographic atrophy.
Clinical Trials[edit | edit source]
The Phase II clinical trial of lampalizumab, known as the Mahalo trial, suggested that the drug could slow the progression of geographic atrophy. However, the Phase III Spectri and Chroma trials failed to confirm these results.
In the Spectri trial, patients treated with lampalizumab did not experience a significant reduction in the progression of geographic atrophy compared to those treated with a placebo. Similarly, in the Chroma trial, there was no significant difference in the progression of geographic atrophy between patients treated with lampalizumab and those treated with a placebo.
Future Development[edit | edit source]
Following the results of the Spectri and Chroma trials, Genentech announced that it would not seek regulatory approval for lampalizumab as a treatment for geographic atrophy. However, the company stated that it would continue to investigate other potential treatments for this condition.
See Also[edit | edit source]
- Geographic atrophy
- Age-related macular degeneration
- Genentech
- Roche Group
- Complement factor D
- Monoclonal antibody
| Lampalizumab Resources | |
|---|---|
|
 |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
